There are now numerous in vitro and in silico ADME alternatives to in vivo assays but how do different industries incorporate them into their decision tree approaches for risk assessment, bearing in mind that the chemicals tested are intended for widely varying purposes? The extent of the use of animal tests is mainly driven by regulations or by the lack of a suitable in vitro model. Therefore, what considerations are needed for alternative models and how can they be improved so that they can be used as part of the risk assessment process? To address these issues, the European Partnership for Alternative Approaches to Animal Testing (EPAA) working group on prioritisation, promotion and implementation of the 3Rs research held a workshop in November, 2008 in Duesseldorf, Germany. Participants included different industry sectors such as pharmaceuticals, cosmetics, industrial-and agro-chemicals. This report describes the outcome of the discussions and recommendations (a) to reduce the number of animals used for determining the ADME properties of chemicals and (b) for considerations and actions regarding in vitro and in silico assays. These included: standardisation and promotion of in vitro assays so that they may become accepted by regulators; increased availability of industry in vivo kinetic data for a central database to increase the power of in silico predictions; expansion of the applicability domains of in vitro and in silico tools (which are not necessarily more applicable or even exclusive to one particular sector) and continued collaborations between regulators, academia and industry. A recommended immediate course of action was to establish an expert panel of users, developers and regulators to define the testing scope of models for different chemical classes. It was agreed by all participants that improvement and harmonization of alternative approaches is needed for all sectors and this will most effectively be achieved by stakeholders from different sectors sharing data.
Introduction
Evaluation of the rates and extents of absorption, distribution, metabolism, and excretion (ADME) of compounds is a fundamental part of the in-depth understanding of the toxicological and pharmacological effects they may exert on humans and animals. Traditionally, ADME studies have been carried out using animals and, for certain industrial sectors, in vivo studies still have to be performed according to European regulatory frameworks. However, the development of non-animal test methods (i.e. ''alternative'' assays which may include in silico and in vitro models, as well as decision tree strategies to reduce animal testing) is strongly promoted within all industrial sectors in order to produce safety data that are more relevant to humans and to replace animal studies currently in use (Horizontal Legislation, 2008, agro-chemicals EU regulation: Council Directive 91/414 revision) . The urgency for the cosmetic industry is more imminent since the use of certain in vivo animal studies (e.g. genotoxicity, eye and skin irritation and acute toxicity) has already been banned due to the 7th Amendment to the Cosmetics Directive and in vivo ADME studies will be banned in 2013.
In vitro biotransformation assays have been used routinely for decades but none have been validated for risk analysis (Blaauboer et al., 1994; Coecke et al., 1999) . Nevertheless, the value of in vitro assays in assessment of chemicals is exemplified by their use in the drug candidate selection process in the pharmaceuticals industry which has proved quite successful in providing estimates of human bioavailability and clearance (Cai et al., 2006) . The Organisation for Economic Co-operation and Development Technical Guideline (OECD) TG 428 describes an in vitro assay for testing dermal absorption but no similar detailed Guidelines exist with respect to the use of sub-cellular fractions, primary cells and in silico methods to predict metabolism (biotransformation). Nevertheless, tiered testing strategies for assessing metabolism have been suggested and reviewed previously (ECVAM, 2002; Coecke et al., 2005a) . Models used to identify ADME properties (as well as organ-specific toxicities of chemicals) are summarised in Table 1 , together with information regarding recommendations by the regulatory authorities and validation status. There is also a number of Quantitative Structure Activity Relationship (QSAR) models that are available to both industry and academia and these include but are not limited to the OECD toolbox (Table 2) . Supporting activities from industry, European Commission and Academia to enable the development of non-animal models are summarised in Table 3 .
An EPAA workshop was held in Duesseldorf on 24th/25th November, 2008, and was attended by scientific experts in the pharmaceutical, chemical, pesticide and cosmetic industries, by regulators, as well as by academia. Participants included representatives of the Scientific Committee on Consumer Safety (SCCS), European Centre for the Validation of Alternative Methods (EC-VAM), European Food Safety Authority (EFSA) and Directorate General (DG) for Research. The aim of the workshop was to discuss how to implement in vitro ADME test systems as part of Integrated Testing Strategies (ITS) for the testing of cosmetics, pharmaceuticals and industrial chemicals and pesticides (including agro-chemicals such as herbicides, fungicides, or insecticides). The present report presents the outcome of the break-out group discussions in describing how in vitro assays may be used within different industry sectors and how regulators view in vitro data. It also outlines international projects aimed at developing alternative test models. In addition, the break-out sessions discussed the suitability of in vitro approaches to systemic toxicity and hazard identification for target organs and steps required to attain regulatory acceptance. Emphasis is placed on in vitro assays and their use in risk assessment issues including preliminary risk assessment such as for prioritisation and deprioritisation, rather than in targeted risk assessment per se, since this is markedly different between industry sectors and is out of the scope of this paper.
Regulatory framework and views from regulators
The use of animal assays is different across industries, whereby in vivo studies are required in one sector but banned in another. An overview of these differences and the agencies which affect the use of animals is described below.
Pharmaceuticals
The European Medicines Agency (also known as the EMA) is a European agency which evaluates pharmaceuticals. In the USA, the equivalent agency is the Food and Drug Administration (FDA). Both the EMA and FDA evaluate and monitor products, as well as developing technical guidance (and guidance documents) and providing scientific advice to sponsors. According to EU Directives (EU Directive 65/65/EEC, 1965 and subsequent amendments), in order to bring a drug onto the market and before it has even been tested ''first in man'' its safety should be tested in animals -with the exception of certain genotoxicity tests (e.g. Ames assay). The Directive recommended that the use of animals should be limited for ethical and animal protection and welfare reasons and efforts should be made to develop new techniques which would produce the same quality of information as in vivo studies. It was for this reason that ECVAM was created in 1992, following a Communication from the Commission to the Council and the Parliament in October 1991. The requirement in Directive 86/609/EEC was to protect animals used for experimental and other scientific purposes and to actively support the development, validation and acceptance of methods which could reduce, refine or replace the use of laboratory animals. Therefore, although the pharmaceutical industry continues to develop new non-animal assays, this industry has not been pressured by regulators into switching from in vivo assays to in vitro alternatives to test drugs during the development process.
Chemicals
EU Chemicals Agency (ECHA) is the agency which manages the technical, scientific and administrative aspects of the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) regulation. The REACH regulation came into effect in June 2007 and was designed to regulate the manufacture, import, marketing and use of industrial chemicals (including ingredients used for formulations regulated otherwise such as pesticides and cosmetics). Manufacturers, importers and downstream users must demonstrate that the manufacture/import/use of a substance does not adversely affect human health and that risks are adequately controlled. This applies only to chemicals that are produced and/ or imported in volumes of 1 tonne or more per year and it was expected to apply to tens of thousands of existing and new chemicals but over 143,000 chemical substances marketed in the European Union were pre-registered by the 1 December 2008 deadline (http://echa.europa.eu/sief_en.asp; Hartung and Rovida, 2009 ). The need for determining the toxicokinetics (TK) profile is listed in Annex 1 (Section 1.0.2) of the legislation but in Annexes (VII-X) it is not specifically required and its consideration is needed only if these data are available (Annex VIII-X). However, REACH does provide guidance (guidance on information requirements and chemical safety assessment, Chapters R.7C and R.8) on the use of TK for selection of dose, route of administration and testspecies, as well as on route-to-route extrapolation in the derivation Table 1 In vitro models used for identifying ADME and specific organ toxicity.
Endpoint
Organ Model Comments
Absorption
Intestinal absorption, P-gp efflux Intestine Caco-2 cells (Hubatsch et al., 2007) Validated for prediction of substrates or inhibitors of Pglycoprotein (Elsby et al., 2008 ) MDCK (Irvine et al., 1999) Absorption values may vary, depending on multiple factors (culture, passage etc.) PAMPA membrane, artificial lipid layers (Avdeef et al., 2005) New model validated as more predictive than PAMPA model Dermal absorption Skin Human skin static or flow-through diffusion cell models, using (partly) standardized in vitro conditions and human, rat or pig skin OECD and EU guidelines are available (EU SANCO 222 and OECD TG 428, SCCS/1358/10) Absorption across the BBB Blood:brain barrier Brain microvascular endothelial cells (Porcine, bovine), cell lines, artificial lipid layers (Garberg et al., 2005; Prieto et al., 2004) No single model predictive, a battery of tests recommended (Garberg et al., 2005; Prieto et al., 2004) Metabolism (Braun et al., 2006) Models which reflect specific but not all processes in vivo neural development. Based on mechanistic processes in vivo. Reviewed by Coecke et al., 2007 Re-aggregating brain cell culture (Braissant et al., 2002) Primary dissociated culture (Bal-Price and Brown, 2001) Immortalized human and rodent cell lines (Hong et al., 2003; Coecke et al., 2002) Acute Systemic Toxicity Standard cytotoxicity endpoints, e.g. MTT, NRU using nonhepatic cell lines (e.g. 3T3), non-metabolizing cell type (e.g. V79) cells transfected with specific CYPs ), metabolic competent model (primary hepatocytes)
Can be used as part of decision-tree testing strategies for acute systemic toxicity and TK with respect to the requirements of the EU REACH legislation (Combes et al., 2008) . ACuteTox program to replace in vivo acute toxicity of a DNEL. Each chemical should be registered with ECHA, along with information on properties, uses and safe handling practices.
If based on the current regulations, REACH will take many years and require vast numbers of animals (the latter number is under strong dispute and ranges between 9 million (ECHA, 2009) and 54 million (Hartung and Rovida, 2009) ). Therefore, the REACH regulation challenges the chemicals industry to develop rapid, relevant, cost-effective in vitro assays to reliably predict human toxicity. In addition to drawbacks such as lack of regulatory acceptance another challenge for in vitro assays is that multiple models are needed to replace one in vivo model.
Pesticides
The European Food Safety Authority (EFSA) is a European agency whose role is to provide independent scientific advice and information in the form of opinions and technical reports to support Community legislation and policies and to collect and analyse data allowing assessment and monitoring of risks in the food and feed sector. The work of EFSA is mainly carried out in different expert panels dealing with, besides other food related fields, for instance with food additives, genetically modified organisms, food contaminants, transmissible animal diseases and pesticides and their residues. In a new regulation (EU, 2010), the EU Commission recommended that alternative models should include in vitro and in silico methods, as well as reduction and refinement of in vivo tests. Specifically for ADME determination, the EU Commission favoured the use of in vitro models from the same species as those used in pivotal studies and in human materials (microsomes and intact cell systems).
A risk assessment method considering the 3Rs currently explored by the EFSA is the Qualified Presumption of Safety (QPS) approach for micro-organisms. The QPS approach is based on the presumption that if for a taxonomic group of micro-organisms safety concerns can be excluded, any strain of this group can be considered as safe and that consequently further assessment (also employing animal tests) can be waived, thus reducing unnecessary animal tests.
In the European Union (EU) risk assessment and authorisation of plant protection products (PPPs) was at the time of the workshop carried out according to the provisions laid down in Council Directive 91/414/EEC (EFSA, 2007) . This directive has been replaced by Regulation (EC) 1107/2009 of the European Parliament and the Council which will be fully applicable by 14th June 2011 (EU, 2010) . PPPs that are designed to control pests are toxic by definition and are normally actively brought into the environment. Therefore, extensive testing before any decision on authorisation is mandatory. Testing requirements for the assessment of active substances with respect to possible human health effects include a battery of in vivo tests (acute, subchronic and chronic tests, reproduction toxicity) and are laid down in Annex II to Directive 91/414/EEC while in Annex III testing requirements for the final plant protection product are listed. The same data requirements are laid down also in the new regulation.
In an opinion that was formally adopted in 2007 (EU, 2007) the PPP and their residues (PPR) panel has provided recommendations for a revision of the data requirements of the directive and the new regulation, respectively. Several of these recommendations would reduce animal testing and animal use in the future. Recommendations given are for instance:
Considering the application of PBBK modelling for assessing ADME. Waiving dermal acute tests when the oral toxicity and dermal absorption is low. Waiving in vivo genotoxicity tests when in vitro tests are negative. Employing the local lymph node assay for the assessment of skin sensitisation. Reviewing the questionable requirement of a 1-year dog study. Waiving, under certain circumstances, the conduct of a carcinogenicity study in mice.
Within the frame work of a new guidance document on the definition of pesticide residues for dietary risk assessment, the PPR Panel Unit is exploring on a large scale the applicability of alternative scientific tools not involving animal testing, like read-across and grouping of chemicals, QSAR and also the TTC approach for the assessment of the toxicity of pesticide metabolites that are present in food commodities.
Cosmetics
The Scientific Committee on Consumer Safety (SCCS) is an independent scientific committee (managed by the Directorate General for Health and Consumer Protection of the European Commission), which provides scientific advice to the Commission on non-food related issues. Cosmetics legislation is different from that of other sectors and is, across the EU, based on the Cosmetics Directive 76/ 768/EEC (EU, 1976) . The 6th Amendment to the Directive (EU, 1993) requires that for each cosmetic product a safety dossier is available based upon the risk assessment of the individual ingredients (Pauwels and Rogiers, 2004) and not on that of the final product, as is the case in the USA. The 7th amendment (2004) prohibited the testing of finished cosmetic products in animals. Furthermore, a marketing ban on cosmetic ingredients tested in vivo for genetic toxicity, acute toxicity, eye irritation and skin irritation, came into effect on 11th March, 2009. The ban on reproductive toxicity, repeat dose toxicity and TK is expected to become effective in 2013. Whereas clear testing and marketing deadlines (11th March 2009 and 11th March 2013) are mentioned in the legislative texts, it is also clear that the scientific progress that would allow meeting these deadlines is not yet achieved. It is therefore urgent for the cosmetics industry to develop validated assays that fully replace animal studies for these endpoints in the future.
Although the SCCS welcomes the use of alternative methods once they have been validated, the Committee is confronted with the fact that still today the majority of the results present in the safety dossiers are based on animal studies. In particular, for active 
Endpoint
Organ Model Comments (Dierickx and Scheers, 2002; Clothier et al., 2006; Vignati et al., 2005) , HPCT-1E3 model (Kneuer et al., 2007) , Fa32 cells, HepG2 cells (Dierickx, 2000) , genetically engineered NIH-3T3 or V79 cells (Bull et al., 2001) testing with in vitro basal cytotoxicity models -initiated in 2005 (Clemedson et al., 2006) Long-term toxicity Nephrotoxicity cell lines: RPTEC-TERT1 (Wieser et al., 2008) and HK-2 (6th Framework STREP: Predictomics -Short-term in vitro assays for long-term toxicity (Jennings et al., 2009) These cell lines are being used in Predict-IV ingredients, a Margin of Safety (MoS, see Section 3) is calculated, based upon the lowest ''no observed adverse effect level'' (NOAEL), obtained either via a repeated dose toxicity test or a developmental toxicity study. Furthermore, the dermal absorption value and the calculated exposure level are also taken into consideration in the MoS calculation. Together with the results from skin/eye irritation tests, skin sensitisation assays and mutagenicity/genotoxicity screening batteries, the safety evaluation commonly is completed.
In the cosmetic field, specific additional studies are only performed with the purpose of elucidating mechanisms and/or to reduce TK or toxicodynamic underlying the minimal MoS value of 100. With the exception of the in vitro dermal absorption study, separate TK/biotransformation studies do not form key parts of current cosmetic dossiers. This, however, does not imply that the cosmetic sector would not be interested in the development of such alternatives -quite the opposite. One example is the development of sound xenobiotic biotransformation systems (e.g. appropriate functional cell lines) that could subsequently be used in an integrated approach next to repeated dose toxicity studies, developmental and/or mutagenicity/genotoxicity studies and possible alternative non-animal methods. Past experiences have shown that in vitro methods do not deliver reliable results and, together with a lack of a sound metabolic system, may constitute a major hurdle in the development of relevant in vitro assay systems.
In the cosmetic area, in addition, the availability of a good in vitro mutagenicity/genotoxicity battery is crucial. An in-depth study of 194 SCCP dossiers between 2002 and 2006 showed that the in vitro predictive potential alone is insufficient. Indeed, in that period 19 compounds were found positive in vitro, but negative in the confirmatory in vivo assays, meaning that these compounds would have been lost without the overriding animal testing possibility (Rogiers and Pauwels, 2008) . With respect to skin sensitisation, an in vitro method that would predict the conversion of a pro-hapten into a hapten would be a significant improvement. Finally and importantly, it has repeatedly been acknowledged that examination of biotransformation and TK in general appear to be the ideal starting point for future long-term toxicity 3R-strategies.
Use of in vivo and in vitro assays for risk assessment by different industry sectors
Risk assessment in all sectors usually consists of hazard identification, dose-response assessment (together hazard characterization or effects assessment) and exposure assessment (which, together with effects assessment, forms the risk characterization) (Van Leeuwen, 2007) . Animal data is used to extrapolate to humans and specifically to estimate the exposure level which would lead to a specific level of risk (for non-threshold effects) or a threshold below which no adverse affects are measurable (for threshold effects). A default combined safety factor in use for extrapolation of animal data to (sensitive) humans is 100 and has been used by FDA since the mid-50s (Lehman and Fitzhugh, 1954) . It has since been adopted by the Joint FAO/WHO Expert Committee on Food Additives (JECFA) and by the Joint FAO/ WHO Expert on Pesticide Residues (JMPR) to define the Acceptable Daily Intake (ADI) (Truhaut, 1991) . For other chemicals (at least in the EU) such as industrial chemicals and biocides, the MoS is calculated using two main scaling safety factors, namely, inter-species differences and intra-species differences (Renwick and Lazarus, 1998) . It is used to extrapolate from a group of test animals to an average human, taking into account inter-species differences in kinetics and dynamics and variability in human kinetics and dynamics to account for sensitive subpopulations (Fig. 1) . Fig. 2 is a general scheme, generated as a result of break-out group discussions, on the use of alternative approaches used by different industrial sectors and how they are often used as compounds progress from identification to products, along the development pipeline. Naturally, there are a number of similar approaches where it is not only ethical to avoid animal testing but it makes good business sense to screen compounds for both efficacy and safety using appropriate non-animal models. The point at which animal tests come into the research and development process may be driven by regulation or by the lack of an alternative for the evaluation being undertaken. It should be Table 2 In silico models used for identifying specific organ toxicity and ADME properties.
Model Comment
OECD QSAR Application Toolbox Incorporates information into a logical workflow by grouping chemicals into chemical categories (www.oecd.org).
Evaluates the hazard based on the overall data set of the category, which must not have every chemical tested for every endpoint. Read-across from one tested chemical to an untested chemical is carried out to fill the data gaps TOPKAT (Toxicity Prediction by Komputer Assisted Technology) A statistically based system consisting of a number of robust, cross-validated QSAR models (www.accelrys.com) derived from large data sets of toxicological information from the literature. Chemicals are characterized according to structural, topologic, and electrotopologic indices. This system contains models based on data from 1258 compounds (www.accelrys.com) and can differentiate between irritants and non-irritants DEREK (Deductive Estimate of Risk from Existing Knowledge) A knowledge based system comprising a number of structural rules (based on strongly acidic and basic features which relate to the parent molecules) that aim to encode structure-toxicity information with an emphasis on mechanisms (Sanderson and Earnshaw, 1991) 
DSS (Decision Support System)
The DSS SICRET (Skin Irritation Corrosion Rules Estimation Tool) model consists of a number of rules (known as the Gerner rules) based on physicochemical characteristics (such as melting point, logP and aqueous solubility) to exclude irritation, and structural alerts to include and predict corrosive chemicals (SICRET) and irritants (Saliner et al., 2007) 
MEGen (Model Equation Generator)
This is a free web-based PBBK model equation generator and parameter database developed at the Health and Safety Laboratory as part of a joint industry project promoting the rapid generation of PBBK models (http://xnet.hsl.gov.uk/ megen) ECOSAR A library of QSARs which predicts aquatic toxicity and an expert system for selecting the appropriate QSAR OncoLogic Ò Cancer Expert System: Predicts concern levels for cancer potential based on ''knowledge rules'' PBT Profiler
Estimates Persistence, Bioaccumulation and Toxicity and distribution in water, soil, sediment, and air using a Level IIImulti-media model MultiCASE
The Multiple Computer Automated Structure Evaluation (MultiCASE) program uses a special type of algorithm to automatically identify chemical moieties that could lead to genotoxicity and deselect chemicals which lack structural alerts (e.g. high molecular weight chemicals such as polymers and chemicals which are only exposed dermally) ADMEWorks
ADMEWorks can be used for predicting chemical and biological properties of compounds based on molecular structures (physicochemical, topological, geometrical, and electronic properties) and data on the property of interest (Hayashi et al., 2005 ) Vitic Nexus database A chemically intelligent database, which can recognise and search for similarities in chemical structures (www.lhasalimited.org) pointed out that strategies that involve a small number of animals at early stages of development may actually reduce the overall numbers of animal procedures that may have identified a toxicological issue much later in development. Therefore refinement and reduction are often forgotten but still very important steps in the overall 3R target. In all sectors an initial evaluation of new chemicals is often made based on their physicochemical properties, e.g. solubility, Main objectives include mapping of past and current 3R activities to better inform the planning and prioritisation of subsequent actions; prioritisation, promotion and implementation of future research based on the application of the 3Rs; dissemination and implementation of best practice in the use of the 3Rs. EPAA has recognised the need for interaction between academia, industry and regulators to find ITS, or ''building blocks'', which are reproducible, transferable and mechanistically predictive. Major challenges in validating alternative assays were discussed during an EPAA-ECVAM Workshop on 'Overcoming barriers to validation of non-animal partial replacement methods/Integrated Testing Strategies' in 2008 (Kinsner-Ovaskainen et al., 2009) ECVAM ECVAM works in co-operation with other organizations to develop standardized and validated methods for regulatory purposes.
Inter-species difference
Regulators have to be confident in the alternative tests and, in order to achieve this, in vitro toxicity studies should be carried out according to Good Laboratory Practice (GLP). The ECVAM Workshop Report concluded that the OECD documentation on GLP should be applied as far as possible (Cooper-Hannan et al., 1999) . This lead to the publication of an OECD Advisory Document in 2004, which outlined the ''Application of the Principles of GLP to in vitro Studies'' (OECD, 2004) . As an aid to the production of robust data, an ECVAM Task Force Report provided guidance on good cell culture practice (GCCP) (Coecke et al., 2005b) . ECVAM has focussed on the use of human models ACuteTox
This project is an EU-funded project (6th Framework Programme (FP6)) focussing on the development and pre-validation of a simple and robust in vitro testing strategy for prediction of human acute systemic toxicity. The aim is to replace animal acute toxicity tests currently used for regulatory purposes by in vitro tests which allow for detection of bioactivated toxins. The project uses the paradigm that acute toxicity of a compound is determined by its basal cytotoxicity. However, this may not hold for many compounds for which acute toxicity is due to specific toxicity, rather than basal toxicity. This has been addressed in Work Package 6.1 in which the cytotoxicity reference chemicals, as well as 5 additional compounds which require bioactivation, have been compared primary hepatocytes (metabolically component) and HepG2 cells (relatively poor metabolic competence). Compounds which are more toxic to hepatocytes suggest that they require bioactivation to elicit cytotoxicity. In Work Package 7 (investigating neurotoxicology, nephrotoxicity and hepatotoxicity), different measurements of cytotoxicity were compared with the MTT assay. Following statistical analysis and data mining, the best combinations of in vitro tests that give a relatively good correlation with in vivo (rat and human) data were identified. Thirty-three compounds will be tested in the selected assays under blind conditions and the results will be used retrospectively to validate the preliminary testing strategy Predict-IV This project sets out to profile the toxicity of new drugs using a non-animal-based approach integrating toxicodynamics and biokinetics. The aims include the development of new strategies for drug safety assessment focusing on non-animal test systems.
Other goals are to deduce MoSs and identify early biomarkers in human hepatotoxicity, nephrotoxicity and CNS toxicity. Long-term human models for non-target organ specific toxicity and bioactivation systems and co-culture models for specific toxicity are also being evaluated. The aim is to analyse samples, using genomic, transcriptomic and metabolomic profiling, from each model which have been treated with the same compound and compare outcomes from each endpoint. The compounds selected are those with well-described toxicities and kinetics in animals and partly also in humans OSIRIS OSIRIS (Optimised Strategies for Risk Assessment of Industrial Chemicals through Integration of Non-Test and Test Information) aims to develop an ITS to enable a significant increase in the use of non-testing information for regulatory purposes. One of the so-called ''interlinked Research Pillars'' focuses on exposure-informed testing (triggering and waiving). The reduction of the use of animals could be implemented in a number of ways and some of these issues have been discussed previously (Barton et al., 2006; Creton et al., 2009) . Results from recent studies are shown in the ORISIS web site http://www.osiris.ufz.de/index.php?en=18585 START-UP 3Rs ''START-UP'' is a coordination and support action coordinated by Prof. Vera Rogiers. A number of small 3Rs projects are supported which aim to establish a better link between academia and industry. The latest progress report is available at ftp:// ftp.cordis.europa.eu/pub/fp7/docs/alternative-testing-progress-report-2009_en.pdf EU Directorate General (DG) for Research
As a result of the high priority of developing alternatives to existing repeated dose systemic toxicity testing, the EU Directorate General (DG) for Research and Colipa to formulate a specific research strategy to address this problem. Two of its main objectives are to (1) encourage collaboration between industry and academia to gain leadership in key technology areas and (2) promote ideas by supporting basic research at the scientific frontiers (implemented by the European Research Council). There are several FP6 projects still running in DG RTD which apply in vitro and in silico methods for human safety assessment. FP7 includes a significant number of new initiatives ranging from ITS to coordination to optimization of the use of the limited financial resources. More information on the on individual research projects and support actions can be found in the 2009 Progress Report on Alternative Testing Strategies http:// cordis.europa.eu/documents/documentlibrary/106691831EN6.pdf logKow P, pH, pKa and molecular weight. Assumptions as to likely corrosive effects can be made if the chemical has an 'extreme' pH value (P11.5 or 62), especially if it is to be applied topically (it may be corrosive or a skin or eye irritant, for example). In order to screen potentially thousands of compounds, many companies incorporate the use of in silico models (listed in Table 2 ). As part of a risk assessment of possible systemic toxicity, in addition to the characterization of the hazard, the likely systemic exposure of the chemical has also to be taken into account. This will differ between industries since pharmaceutical companies usually aim to reach a significant target therapeutic plasma concentration and assess the compound on a risk-to-benefit basis. Since the intended exposure target is potentially high, consideration of the risk-to-benefit is important in the pharmaceutical industry (more so than the chemical or cosmetics industry) and the weight of this ratio may also differ according to the different product types (e.g. cancer therapy versus diabetes). For chemicals industries it is key to assess the likely exposure under occupational conditions.
In vitro assays are used by all sectors of industry for safety testing but the need for in vitro models in risk assessment will differ according to the needs of the different industrial sectors and the specific question that needs to be addressed. Appropriate models of varying complexity are often used by different sectors to address specific organ toxicity. For example, there are a number of models used for investigating liver metabolism and toxicity which have certain characteristics as well as limitations in their use (summarised in Table 4 ). In vitro data may be more suitable for in-house decision-making within an industry sector, whereas the regulatory agency may ask for much more specific information on an effect seen in vitro (e.g. whether a specific transporter is involved in the clearance of a compound). Exposure-based waiving can be used as in-house method if, e.g. an in vitro assay shows that a target organ would not be exposed to a test compound, in which case, an in vivo study would not be needed.
In the pharmaceutical industry, animal studies have to be carried out for licensing of a medicinal product containing a new active substance but in vitro assays are used for screening, drug candidate selection and drug-drug interaction information for Phase 1 clinical trials. ADME studies here are not necessarily conducted according to regulatory legislation. Moreover, studies which investigate the use of potential drug candidates can be performed under non-GLP conditions, especially for non-standard screening technologies, safety studies performed to support regulatory requirements (e.g. Investigational New Drug (IND) applications) should, in general, be GLP compliant. However, in vitro assays performed to predict toxicity may be carried out according to the FDA draft guidelines (FDA, 2006) . These assays are included in Table 1 . The pharmaceutical industry and, on a less routine basis, the chemical industry employ PBBK models to identify and reduce uncertainties in risk assessment (MacGregor et al., 2001; Delic et al., 2000) . In terms of risk management, it should be kept in mind what constitutes an acceptable risk, depending on the industry and the purpose of the compounds under development.
Once an assessment of the source and likely exposure of a chemical is addressed, the risk can be characterized as an estimation of the incidence and severity of any adverse effects likely to result from actual or predicted exposure. For REACH chemicals, the level of exposure above which humans should not be exposed should be estimated, i.e. the DNEL (Derived No Effect Level). In the risk characterization, the exposure of each human population known to be, or likely to be exposed, is compared with the DNEL. The risk to humans can be considered to be adequately controlled if the estimated exposure levels do not exceed the DNEL. Calculation of the DNEL (Human Limit Value) involves a number of considerations such as uncertainty, extrapolation or assessment factors (inter-species, intra-species, exposure duration, route-to-route etc.) and should not be confused with the NOAEL (usually derived in animals). For agro-chemicals, in vitro assays can be used to compare metabolites produced by mammalian cells with those produced by plants and determine whether the toxicological evaluation of each agro-chemical sufficiently encompasses any crop residues of concern.
The acceptance and validation of in vitro models is most pressing for the cosmetics industry. They must consider the route and extent of exposure, since the skin is the main site of application of cosmetics, as a result, major focus has been placed on dermal absorption for which accepted in vitro methods are available. Other dermal models include human reconstructed skin models for use in genotoxicity testing (Munn et al., 2009) . For other endpoints such as skin and eye irritation, scientifically accepted methods used in combination are being used as alternatives to animal models. In contrast to other sectors, the cosmetics industry is required by law to replace a number of in vivo animal tests with scientifically valid alternative approaches.
Information gained from in vitro assays
In an optimal situation, ADME/TK are cross-cutting issues that are taken into account in all these processes, albeit not literally or specifically required in various sector legislations. To this end, scientifically justifiable -but not legally required -information may come from in vivo as well as in vitro assays which can be used by one or more sectors to determine ADME properties as well as understanding mechanisms of action. Examples of information gained from in vitro models are described below and listed in Table 1 . A major challenge is that in vitro methods are needed that allow for a quantitative assessment of effects in vivo.
Absorption/exposure
Safety assessors from all industry sectors will need to evaluate the exposure of a chemical to human health, whether it is intestinal absorption from an orally dosed drug, systemic exposure from Fig. 2 . Target diagram on the use of alternative approaches in the ADME safety testing area by different industrial sectors. The target for each sector is to undertake more extensive in silico and in vitro evaluation of new chemical entities in early development so that fewer animal studies are needed as the development process moves towards animal testing that is often a regulatory requirement. Although all sectors actively pursue alternative approaches for ethical and practical reasons, the cosmetics industry is actually prohibited from using animals for specific toxicity endpoints. (Diagram prepared by Jon Heylings). a dermally applied cosmetic or accidental exposure from a pesticide. Whereas the pharmaceutical industry is aiming to have good systemic exposure (high bioavailability), the chemical, pesticide and cosmetics sectors are likely to develop chemicals which are poorly absorbed. A number of cell lines, such as Caco-2, are routinely used to determine intestinal absorption. When used as part of a simulation model that takes into account solubility and dissolution in the gastrointestinal tract as well, they give a good prediction as to the extent of absorption . Likewise, cell lines have been employed to predict penetration across the blood brain barrier, although these models still require some further development. The most relevant route of exposure for cosmetics, industrial chemicals and pesticides is the skin (although exposure via inhalation and the oral route can be very relevant as well), for which static or flow-through diffusions cell models have been standardized (as least in part) for use with human, pig and rat skin in OECD and EU context (OECD TG 428, (SANCO, 2004) ). Moreover, there is on-going revision of the current guidance document on dermal absorption (SANCO, 2004) .
Metabolic pathway identification and clearance
The liver is the main site of metabolism of xenobiotics and therefore the majority of in vitro models to determine metabolic pathways and clearance are hepatic (hepatocytes, S9, microsomes etc., Tables 1 and 4). For the potential occupational exposure of chemicals via the dermal route, metabolism in the skin is of importance since it has been shown to possess a number of drug metabolizing enzymes (Oesch et al., 2007) . In vitro models used to evaluate skin metabolism include normal keratinocytes, cell lines such as HaCaT cells and ex vivo human skin (Table 1) . For the pharmaceutical industry, knowledge of the enzymes involved in the metabolism of a compound can provide information of the likelihood of drug-drug interactions, possible problems due to polymorphic enzymes, disease, gender and age; and potential reactive metabolites. So-called ''phenotyping'' information can be used to provide individualized health care and stratified clinical trials. For cosmetics, human liver microsomes have been used to screen hair dyes for their potential to form reactive intermediates rather than carrying out in vivo assays which are also more labour intensive and expensive .
Many researchers focus on the cytochrome P450s (CYPs) since these are the major phase 1 enzymes responsible for the metabolism of the majority of pharmaceuticals on the market (Zuber et al., 2002) . However, there are other non-CYP enzymes which may also metabolise compounds, such as the phase 1 alcohol dehydrogenases (Kollock et al., 2008) ) and the phase 2 enzymes, sulfotransferases (SULTs), UDPGA-glucuronosyltransferases (UGTs) and glutathione S-transferases (GSTs) (Evans and Relling, 1999) . It is important to include phase 2 enzymes such as GSTs in Table 4 In vitro liver models and their characteristics and limitations. Short-term study Extrapolation to the in vivo situation limited
Artificial system
Modified according to Coecke et al. (2006) , Guillouzo (1998) , Plant (2004) and Pelkonen et al. (2004) . metabolic studies to more completely reflect the physiological situation. In many cases phase 2 enzymes can detoxify substances and/or their phase 1 metabolites (e.g. paracetamol toxicity (Schnackenberg et al., 2008) ). Identification of the enzyme(s) involved in the metabolism of a compound and understanding how metabolism may vary across and within species and across human subpopulations, e.g. poor metabolizers versus extensive metabolizers (Bogni et al., 2005) , is very important for risk assessment (choice of test-species and possible use of a larger intra-species extrapolation factor). Another important use of in vitro metabolic studies is the use of these data to confirm the MoS (see Section 3). The use of a general 3.2 kinetic factor reflecting inter-individual variation may not cover metabolism by poor metabolizers or extremes of ages (Renwick and Lazarus, 1998; Dorne et al., 2002 Dorne et al., , 2003 Dorne and Renwick, 2005) ; therefore, the kinetic factor can be confirmed or adjusted according to the metabolic phenotype.
Selection of most relevant species
Traditionally, the evaluation of species differences in metabolite formation has not been considered on a routine basis, mainly due to the uncertainty of the contribution of metabolites to the toxic effect. However, it is now evident that species differences in drug metabolizing enzymes can influence the toxicity of a compound across species (Uehara et al., 2008) . Therefore, there is a need to carry out TK studies on rodent and non-rodent species in order to decide on the most relevant test-species for possible human effects testing. For example, according to the FDA guidelines (FDA, 2005) , if a metabolite represents more than 10% of parent compound in human (defined as a major metabolite), then it should be present in the animal species tested. This emphasises the importance of establishing major metabolites produced by different species using in vitro assays so that they can be covered in animal toxicity studies. This line of guidance is also recommended by the EU Commission (EU, 2010). Following on from this, in order to evaluate non-clinical animal toxicology studies, the systemic exposure of the drug (quality, i.e. parent and/or metabolites, as well as quantity, i.e. extent and/or rates of formation) should be considered and compared between the testspecies and humans (i.e. species-specific metabolism). This comparison is reasonable if the metabolic pathways are similar, however, in rare cases, if in vitro assays suggest that major metabolites produced in humans are not evident in animals, then further investigations into the toxicity of the metabolite are necessary. If it can be established that at least one animal testspecies produces major metabolite(s) observed in humans, it can be assumed that the metabolite's contribution to the overall toxicity assessment has been taken into account. The use of in vitro assays, especially in early compound development, allows for selection of compounds and, when possible, the most suitable pre-clinical species, as well as flagging up compounds that may require additional toxicity studies to evaluate the contribution of the metabolites to the toxic effects (Coecke et al., 2005b) .
Drug-drug interactions in pharmaceutical safety evaluation
Drug-drug interactions are most relevant to the pharmaceutical industry since often more than one drug is purposefully given at therapeutic doses to treat multiple symptoms/causes of illness (i.e. polypharmacy). Unfortunately, one drug may alter the pharmacokinetics of the co-therapy drug and result in either the loss of efficacy or increased toxicity of the latter. Metabolic inhibition of drugs can be predicted using human liver microsomes whereas human hepatocytes are considered to be the ''Gold Standard'' for predicting metabolic induction ( Table 1) . Knowledge of potential drug-drug interactions is a vital part of the candidate (de)selection process as well as aiding in the design of clinical interaction trials.
Mechanistic understanding
Significant progress has been made in the understanding of cellular-response networks, i.e. a network of pathways involving a complex biochemical interaction of genes, proteins, and small molecules that maintain normal cellular function. Advances in our knowledge of the pathways are allowing researchers to investigate how they are altered by environmental agents and ultimately lead to toxicity. The US National Research Council (NRC) report in 2007 called for more human-cell-based, high-throughput assays that encompass a multitude of toxicity pathways and in response, NIH (National Institutes of Health) and EPA have entered into a formal collaboration known as Tox21 (Tox21, 2008) . Their aims are to identify mechanisms of chemically-induced biological activity, prioritize chemicals for more extensive toxicological evaluation, and develop more predictive non-animal based models of in vivo biological response. Hopefully, this research will lead to toxicity models that are more scientific and cost-effective as well as models for risk assessment that are more mechanistically-based. Despite the advances, the resulting mechanism-based assays need validation or at least profound scientific evaluation before they can be used routinely. Often, the appropriate prediction evaluation occurs in parallel with assay development and ultimately leads to the streamlining of the assay. Parameters such as stability of solutions, proteins or even cell lines should be checked and standardized. Incubation times, storage, robustness (replicates for statistical analysis) are also some of many considerations companies make when validating assays (McGee, 2006) .
Recommendations from the workshop for in vitro assays
The main priority for all industry sectors is the safety of the products and thus for people, animals and the environment and doing this with a reasonable the number of animals used and, in the case of the cosmetics industry, to replace in vivo assays entirely. Some of the priorities were discussed in break-out groups (each containing representatives from academia and industry and in some, representatives from regulatory bodies) from the workshop and are listed below. The sector(s) to which the priority applies most is shown in brackets. Topics that were discussed were not necessarily the views of all those who participated.
Apply considerations for in vitro assays (all sectors)
Through discussions in the workshop, it was concluded that in order to interpret in vitro data, a number of considerations need to be made which include:
Are in vivo and in vitro concentrations the same and is the in vitro concentration relevant to in vivo? Is the effective concentration the same as the concentration added to the in vitro system? Is the effective concentration in vitro translated correctly to the in vivo concentration? What are the volatility and binding properties (to plastic surfaces and/or to microsomal/cellular proteins) of the compound? This in turn affects the concentration to which the cells are exposed. In order to determine the free fraction of compound, solid phase micro extraction can be used (Pawliszyn, 1995; Vaes et al., 1996) . What is the free concentration of test compound in incubation medium containing different concentrations of serum? The presence of serum can affect the free fraction of a compound as much as reducing it to 1000th of the nominal concentration added.
Consideration of the contribution of multiple organs: In vitro assays focus on one organ, rather than the animal/human as a whole. Therefore, influences of other organs are not incorporated into the model and may cause an under-or over-prediction of a toxic effect. Section 4.1 describes how at least the distribution into multiple organs can be predicted using (physiologically-based biokinetic) PBBK modelling approaches. Consideration of the phenotype: A pre-screening characterization of cell lines, especially if they lack specific bioactivating/ detoxification enzymes, should be carried out in order to interpret resulting data. A common understanding of HepG2 cells is that they have a low metabolizing capacity; however, there are reports of these cells having comparable enzyme activities to primary human hepatocytes (Westerink and Schoonen, 2007a,b) and such activities may be due to the source (and therefore sub-clones) and the type of basal medium used to culture and passage them (which have been shown result in different phase 1 and 2 enzyme activities of HepG2 cells (Hewitt and Hewitt, 2004) ). Consider uncommon effects: Predictive models are based on certain assumptions and known common chemical and physiological processes and, as a result, may miss certain effects. For example, prediction of accumulation of test compounds in bone using in vitro assays has not been described so far.
Standardize and promote in vitro assays (all sectors)
There are many variables in metabolism assays which may affect their outcome; therefore, harmonization of these assays is needed. The harmonization of toxicity tests according to OECD guidelines began in the early 1980s. In addition the testing of the safety and efficacy of drugs is harmonized by the International Conference on Harmonisation (ICH). This has led to the effect of not just standardizing tests but reducing the number of animals used, since regulatory agencies around the world now accept the results of a test conducted according to such guidelines. Nevertheless, researchers have to work hard to convince regulators and the scientific community that some in vitro/in silico methods are sufficiently reliable to be used, albeit not yet for systemic toxicity endpoints. It was felt that stronger involvement of regulators in the early stages of the process should be encouraged so that it can be clarified through dialogue what information is needed for an assay to be validated. Additionally, the perception, or weight, of the information from in vitro assays should be correctly assessed and communicated between the researchers and regulators.
Avoidance of false positives (all sectors)
Care must be taken not to be ''overly-efficient''! For one company, due to efficient in-house de-selection of test compounds, there were no positive genotoxic compounds in in vivo studies. Since there are false positive results from single and combined in vitro genotoxicity assays, de-selection of all positive responses in these assays may prevent the development of promising nongenotoxic compounds. Negative outcomes in in vitro genotoxicity assays (which exhibit high sensitivities) are accepted by regulatory agencies; however, this is not the case for other endpoints such as skin irritation. One Colipa (European Cosmetic Toiletry and Perfumery Association) project in progress is to refine current assays to avoid generation of false positives (project entitled ''Reduction in the ''false positive'' rate of in vitro mammalian cell genotoxicity assays'', co-sponsored by Colipa, ECVAM and UK NC3Rs); likewise, the FDA is striving for highly predictive systems to avoid false positives.
Mechanism-based toxicity assays should be further developed and validated (all sectors)
Known toxic and adverse effects should also be defined for the kidney, heart, lung, CNS, immune system, adrenal and thyroid glands (endocrine disruptors). Information on known substances developed by the pharmaceutical and, if possible, other industries should be collected. This will help develop QSAR models and new assays (including active transport, signalling).
Actions related to in vitro assays (all sectors)
Workshop participants suggested two actions which may aid the interpretation of data generated from in vitro assays, such as:
Integration of information from different models: Integration of data from separate organ in vitro assays may provide a better overview of toxicity. For example, the contribution of gut bacteria may be incorporated into an absorption model to allow the prediction whether a compound is (re)absorbed from the intestine as parent or metabolite followed by possible further metabolism by another organ. Evaluation of assays: Performance assessment and evaluation of in vitro assays is needed with appropriate controls (e.g. positive, negative and reference compounds) to confirm that the assay is functioning. For example, a cytotoxicity assay should include a positive compound which causes significant cytotoxicity (up to 100%) so that the assay can be shown to be sensitive. Likewise, an enzyme induction study should include a vehicle and positive control for the enzyme (e.g. CYP or phase 2 enzymes) under investigation to compare the potency of the induction effect of a test chemical and assess the dynamic range of the induction capacity of the test system. Contract Research Organisations usually do not validate in vitro assays that are not requested on a routine basis. A number of specialised assays are routinely used and these are often optimized in-house. Lastly, the perception of ''validation'' maybe different between companies and regulatory bodies.
Information gained from in silico models
A number of QSAR models exist (shown in Table 2 ) which can be used to prioritize chemicals and compare large numbers of chemicals using standardized criteria. Other mathematical models based on ADME properties are referred to as physiologically-based biokinetic (PBBK) models and are synonymous with physiologically-based pharmacokinetic (PBPK) models and physiologicallybased TK (PBTK) models. The prediction of in vivo PK parameters such absorption, first pass effects and metabolism has been successfully demonstrated using the SimCyp PBPK model, which is a population-based simulator using physicochemical, in vitro and in silico data (www.simcyp.com). In addition to PK prediction models, mathematical ADME models have been developed to assess TK properties (the effect of the chemical on the body) to address the 3R agenda (Bouvier d'Yvoire et al., 2007) . The most predictive are those which are capable of integrating known physiochemical and chemical-specific in vivo, in vitro as well as in silico (QSAR) data (Blaauboer, 2003) . A new paradigm is that toxicity is determined by the critical concentration and time of exposure to the critical compound (or metabolite) at the critical site of action of the compound. Biokinetics is an important part of this paradigm. PBBK models take into account the fact that organs are linked together. Knowledge of in vitro kinetics can be combined with in vitro toxicodynamic data and incorporated into a model to predict in vivo systemic toxicity. An example of this is acrylamide for which in vitro data on neuronal toxicity was known (DeJongh et al., 1999) .
To date, ADME software packages, although showing promising predictive capacities, especially for absorption and distribution, have not yet been sufficiently validated and still require improvements. A report of an expert meeting organized by COST B15 that reviewed the use of QSAR in drug screening (Boobis et al., 2002) suggested that predictions using QSAR are no worse than those made using in vitro tests, and have the added advantage that they need significantly less investment in technology, resources and time. The report went onto describe a lack of confidence in these approaches and that more effort should be made by the software producers towards more transparency, in order to improve the confidence of their consumers. It was also felt that controlled access to data from pharmaceutical companies would help to validate the models.
Recommendations from the workshop for in silico assays

More extensive use of QSAR by all industry sectors
If QSAR is used as the first step in risk assessment, then compounds that are flagged up as toxic can be de-selected, thus providing a 3Rs and cost-effective screening process. The workshop recommended that the basic parameters of the chemical should be considered (e.g. physicochemical properties) as well as its partitioning into the tissues (indicated by the octanol:water partition coefficient versus the fat:blood partition coefficient) and the physiology of the organ (e.g. structure, blood flow, metabolic capacity, etc.). In addition, there should be more data generated to add to the predictive power of models.
Further development of PBBK models (all sectors)
Further developments should combine in vitro and in silico data to feed PBBK models. To this end, increased efforts are needed to develop medium throughput systems to establish absorption (e.g. Caco-2), partitioning coefficients and metabolic parameters for the most important metabolizing organs, i.e. liver and skin. The use of publicly available tools such as the Model Equation GENerator (MEGen, http://xnet.hsl.gov.uk/megen, see Table 2 ) should be encouraged. Resulting PBBK models can be used to prioritize in vitro development projects. In order for a prediction model to be built, the extrapolation between the concentration of a compound in the incubation medium in vitro and the equipotent plasma concentration is a crucial step, involving predictive TK modelling. In this modelling approach, the metabolism of the compound should be taken into account, especially if it is rapidly metabolized and the nominal in vitro concentration is not constant. Drawbacks of in vitro models are that they have been developed mainly for screening purposes by the pharmaceutical industry and are not validated for certain categories of industrial chemicals. Therefore, training with the latter compounds and taking into account uncertainty is needed.
Recommendations by the workshop for refining and reducing in vivo assays
Microdosing (pharmaceutical sector)
This methodology allows for the determination of human pharmacokinetics of test compounds administered at doses much lower than the expected pharmacologically effective or toxic levels (FDA, 2008) . Microdosing has been used as part of human drug clinical testing to evaluate drug ADME (Coecke et al., 2005b) but has not been widely accepted for testing chemicals. This is not used uni-versally and is done on a case-by-case basis. This technology, once installed is cost-effective to study new chemical entities and has the advantage of requiring only very low doses of radiolabelled compounds. One limitation to this technology is that the dose has to be lower than 100 lg, thus if this is significantly different from the therapeutic dose and the pharmacokinetics profile is different, then the low dose pharmacokinetics data may have decreased relevance compared to the toxic/effective concentration. Another disadvantage of this method is that humans are purposely exposed to radiation for biomedical research and its use should therefore be justified (as recommended by the International Commission of Radiation Protection in Publication 62 (ICRP, 1991) ). There are radiation dose constraints for volunteers under different conditions and these are discussed in the recommendations from the ICRP (ICRP, 2007).
Incorporation of additional endpoints (chemical sector)
In order to refine and improve existing in vivo study types, as well as reduce the number of animals used, for chemical testing, it was recommended to increase information gained from one study by incorporating additional endpoints into the study, e.g. using peripheral blood for metabolomics and the micronucleus (MN) test. It is noted that inclusion of more endpoints, e.g. kinetics, may be difficult to implement for small animals, e.g. mice. In addition, inclusion of positive controls for each endpoint may mean extra animals are needed, although, for some endpoints which have sufficient historical data, such as the in vivo MN test, additional positive controls are not an absolute requirement.
Issues in information sharing (all sectors)
The different industry sectors have generated a vast amount of data using similar models; however, the sharing of this data across sectors has not been as fast flowing. The workshop recommended the sharing of in vivo data, coordination and information exchange between research projects and sectors. Companies should be encouraged to share in-house additional data from long-term studies so that in vivo studies are not unnecessarily duplicated and in silico/in vitro methods can be validated. 9. Proposed actions from the ADME workshop to develop further alternative models and the 3R concept 9.1. Immediate actions Assess promising ADME/PBBK approaches which (a) have been entered into the EPAA in-house methods database or directly via member companies (internal) and (b) are available from false positive projects or others (external). Establish an expert panel, including users, developers and regulators, that defines the testing scope for the potentials and limitations of the models with a set of chemicals. Organize a series of follow-ups (with EPAA members, regulators and external stakeholders) to discuss the results and identify gaps and recommend ways forward. To engage the help of ADME experts from the member companies.
Additional actions
Expert follow-up meeting: Review of developments and changes in the last three years with a focus on replacement/cosmetics (Eskes and Zuang, 2005) . Participants should include the previous ECVAM panel, the EPAA workshop participants and selected participants from other sectors. ECVAM will initiate a dialogue with regulatory decision-makers from different sectors to discuss the potential role of ADME concepts for the 3Rs, and make the link to the EPAA. EPAA could invite industries to provide regulators with case studies to clarify/identify (minimal) regulatory requirements. This should include the use of ADME data to allow/support safety decision-making; proof-of-concept. EPAA could call industry members and other contributing parties to make use of the MEGen database and share data on selected compounds (e.g. form consortium) EPAA to assess if creating a ''single portal'' would be useful (ECVAM database, EPAA database, TSAR website etc.). Drafting of a decision paper by the ECHA (in preparation) on the testing proposal provided by companies which will then be distributed to national regulators for consultation. REACHprovides more flexibility which might change mindset of regulators. ECHA has avery strong role in this process, whereas scientific committees (e.g. the SCCP) have a different, advisory role.
Conclusions
Although alternative ADME and toxicodynamics testing approaches have been used for decades, their application to safety testing strategies is of increasing importance, especially in light of new regulations with respect to chemical testing. It is recognised that the current in vitro metabolism models need improvement to offer more reliable information that is usable in safety assessment. To address this issue, an EPAA workshop was held in Duesseldorf in November, 2008, and brought together representatives from the pharmaceutical, chemical and cosmetic industries with those from (inter)national regulatory agencies. There are many alternative approaches used by different industrial sectors as compounds progress from identification to final products. A number of nonanimal approaches not only allow for ethical testing but make good business sense in screening compounds for both efficacy and safety. The point at which animal tests come into safety assessment may be driven by regulations or by the lack of an in vitro model. Strategies that involve a small number of animals at early stages of development may also reduce the overall numbers of animal-based assays much later in development. Therefore refinement and reduction are evenly important challenges in the overall 3R target in the ADME area. In vitro systems that reflect certain aspects of the ADME (and effects) process can be very helpful in the safety assessment process as well as the 3R principal; but, on the other hand, many in vitro systems have their pitfalls, especially with respect to an insufficient reflection of the integrated in vivo physiological ADME conditions and a lack of fully validated assays. The recommendations proposed by representatives from different sectors and companies, which apply to all sectors, to propel the use of in vitro alternatives in the field of risk assessment are summarised below:
Generate open web-based database on in vivo kinetic parameters. Industry data that are already available could be collected in a central database to benefit all sectors. Coordinate effort before generating new data. Expand Applicability Domains of in silico tools. Expand Applicability Domains of in vitro tools and develop new in vitro tools. Obligatory inclusion of blood sampling for TK purposes during toxicity studies. Investigate increased use of human low dose kinetics. Microdosing. Biomonitoring.
The workshop concluded that these assays still need to be improved but that it may be achieved by stakeholders from different sectors sharing data so that universal agreement is reached for harmonization of alternative approaches. Major international project funding programs are on-going to help develop, validate and harmonize in vitro tests and lead to their use as part of the risk assessment of chemicals.
